<DOC>
	<DOCNO>NCT00734526</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose sorafenib give combination temozolomide . The safety combination also study .</brief_summary>
	<brief_title>Phase I Portion Phase I/II Sorafenib With Radiation Temozolomide Newly Diagnosed Glioblastoma Gliosarcoma</brief_title>
	<detailed_description>The Study Drugs : Sorafenib design stop cell growth block formation new blood vessel ( tubes carry blood around body ) , involved growth development tumor . Temozolomide design kill cancer cell damage DNA ( genetic material cell ) . The damage DNA may cause tumor cell death . Study Groups : If find eligible take part study , assign 1 4 group base join study . You remain group entire study . In study , dose study drug different group group , dose also different radiation . During radiation , study drug dose follow : - If Group 1 , take temozolomide . - If Groups 2 3 , take temozolomide low dose sorafenib . - If Group 4 , take temozolomide high dose sorafenib . - During radiation , group take dose temozolomide . After Radiation : - If Groups 1 2 , take high dose temozolomide short cycle high dose sorafenib . - If Group 3 , take low dose temozolomide long cycle lower dose sorafenib . - If Group 4 , take low dose temozolomide long cycle high dose sorafenib . The amount study drug receive may change experience side effect . If time experience intolerable side effect , tell study doctor right away . Study Drug Administration : During Radiation : As part standard care , receive radiation therapy Monday-Friday total 30 radiation treatment ( 6 week ) . Every day receive radiation , take temozolomide mouth day ( maximum 7 week ) . On Monday-Friday , take temozolomide 1 hour radiation therapy . On Saturday Sunday , take temozolomide morning . You swallow temozolomide whole , one right , without chew . If vomit take temozolomide , take capsule next schedule dose . They take empty stomach ( least 1 hour 2 hour eat ) 1 cup ( 8 oz . ) water . Every day receive radiation , take sorafenib mouth 2 time day ( morning evening ) ( maximum 7 week ) . You take sorafenib without food ( 1 hour 2 hour eat ) , least 1 cup ( 8 oz . ) water . If Group 1 , take sorafenib . After Radiation : You take study drug ( ) 4 week radiation therapy end . After 4 week : - If Group 1 2 , Days 1-5 every 28-day study cycle , take temozolomide mouth day . - If Group 3 4 , Days 1-21 every cycle , take temozolomide mouth day . Every day cycle , group take sorafenib mouth 2 time ( morning evening ) . Study Visits : During Radiation : Once week receive radiation therapy , ask drug may take experienced side effect . Your blood pressure measure . Blood ( 3-4 teaspoon ) draw routine test . After Radiation : About 3-4 week end radiation therapy , MRI scan check status disease . On Day 1 every cycle , follow test procedure perform : - You physical exam , include measurement vital sign . - You neurological exam . - You performance status evaluation . - You ask drug may take experienced side effect . - Blood ( 3-4 teaspoon ) draw routine test . On Days 7 , 14 , 21 Cycle 1 Days 7 14 ( 21 ) Cycles 2 beyond , blood ( 3-4 teaspoon ) draw routine test . On Day 1 every cycle ( Cycles 3 , 5 , 7 , ) , MRI scan check status disease . Every week Cycle 1 , blood pressure measure . Length Study : You study 15 month total . You take study early disease get bad experience intolerable side effect . End-of-Study Visit : After go study , end-of-study visit . At visit , follow test procedure perform : - You physical exam , include measurement weight vital sign . - You performance status evaluation . - You ask drug may take experienced side effect . - You neurological exam . - You MRI scan check status disease . - Blood ( 3 teaspoon ) draw routine test . This investigational study . Temozolomide FDA approve commercially available treatment brain tumor . Sorafenib FDA approve commercially available treatment kidney cancer , experimental use brain tumor . In addition , combination temozolomide Sorafenib experimental use brain tumor . At time , combination use research . Up 51 participant take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Histopathologically proven diagnosis glioblastoma . Since gliosarcoma variant glioblastoma , gliosarcoma also eligible diagnosis . 2 . Patients must least 1 block tumor tissue available submission central pathologist analysis gene expression status QRTPCR ; must least 1 cm^2 tumor block cut slide : fresh frozen tumor tissue acquisition also encourage , require . Unstained slide submission without block submission acceptable study entry . 3 . Diagnosis must establish open biopsy tumor resection . Patients stereotactic biopsy eligible.. 4 . The tumor must supratentorial component . 5 . Patients must recover effect surgery , postoperative infection , complication study registration . 6 . All patient must sign informed consent indicate aware investigational nature study . 7 . A diagnostic contrastenhanced MRI CT scan ( MRI contraindicate ) brain must perform postoperatively period surgery initiation radiation therapy . 8 . Therapy must begin &lt; /=5 week recent brain tumor surgery . 9 . History/physical examination within 14 day prior study registration . 10 . Neurologic examination within 14 day prior study registration . 11 . Documentation steroid dos within 14 day prior study registration stable decrease steroid dose within 5 day prior registration . 12 . Karnofsky performance status &gt; /= 60 . 13 . Age &gt; /= 18 year . 14 . Patients wellcontrolled hypertension eligible ( systolic blood pressure &lt; /= 140 mgHg diastolic pressure &lt; /= 90 mgHg ) . 15 . Complete blood count ( CBC ) /differential obtain within 14 day prior study registration , adequate bone marrow function define : Absolute neutrophil count ( ANC ) &gt; /= 1500 cells/mm^3 ; Platelets &gt; /= 100,000 cells/mm^3 ; Hemoglobin &gt; /= 10 g/dl . 16 . Adequate renal function , define : Serum creatinine &lt; /= 1.7 mg/dl within 14 day prior study registration 17 . Adequate hepatic function , define : Bilirubin &lt; /= 2.0 mg/dl within 14 day prior study registration ; ALT &lt; /= 2 x upper limit normal range ( ULN ) within 14 day prior study registration ; AST &lt; /= 2 x ULN range within 14 day prior study registration 18 . Fasting cholesterol &lt; 300 mg/dL ( 9.0 mmol/L ) fast triglyceride &lt; 2.5 time ULN 19. International normalize ratio ( INR ) &lt; 1.5 PT/PTT within normal limit patient anticoagulation treatment 20 . Patients receive anticoagulation treatment agent warfarin low molecular weight heparin may allow participate follow criterion : For patient prophylactic anticoagulation therapy ( lowdose warfarin ) : INR level &lt; 1.5 ; Patients prophylactic dose full dose low molecular weight heparin eligible provide patient active bleed pathological condition carry high risk bleeding ; 21 . ( 20. continue ) Patients fulldose anticoagulant ( e.g. , warfarin ) eligible provide follow criterion meet : ( ) Patient inrange INR ( usually 23 ) stable dose oral anticoagulant stable dose low molecular weight heparin . ( b ) Patient active bleed pathological condition carry high risk bleeding . 22 . If patient 's mental status preclude his/her give inform consent , write informed consent may give responsible family member . 23 . For female childbearing potential , negative serum pregnancy test within 72 hour prior start temozolomide 24 . Women childbearing potential men must agree use adequate contraception ( barrier method birth control ) prior study entry duration study participation . Men use adequate birth control least six month last administration sorafenib temozolomide . 1 . Prior invasive malignancy ( except nonmelanomatous skin cancer ) unless disease free &gt; /= 3 year . 2 . Recurrent multifocal malignant glioma 3 . Metastases detect tentorium beyond cranial vault . 4 . Prior chemotherapy radiosensitizers cancer head neck region ; note prior chemotherapy different cancer allowable . 5 . Prior use Gliadel wafer intratumoral intracavitary treatment permit . 6 . Prior radiotherapy head neck ( except T1 glottic cancer ) , result overlap radiation field . 7 . Severe , active comorbidity , define follow : Cardiac disease Congestive heart failure &gt; class II New York Heart Association ( NYHA ) . Patients must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month ; Cardiac ventricular arrhythmia require antiarrhythmic therapy ; Acute bacterial fungal infection require intravenous antibiotic time registration ; Chronic Hepatitis B C infection ; 8 . ( 7. continue ) Chronic Obstructive Pulmonary Disease exacerbation respiratory illness require hospitalization preclude study therapy time registration ; Hepatic insufficiency result clinical jaundice and/or coagulation defect ; 9 . ( 7. continue ) Known history symptom laboratory result consistent Acquired Immune Deficiency Syndrome ( AIDS ) base upon current CDC definition ( note , however , HIV test require entry protocol . The need exclude patient AIDS protocol necessary treatment involve protocol may significantly immunosuppressive ) ; Major medical illness psychiatric impairment investigator 's opinion prevent administration completion protocol therapy ; 10 . ( 7. continue ) Active connective tissue disorder , lupus scleroderma , opinion treat physician may put patient high risk radiation toxicity ; Arterial thrombotic embolic event cerebrovascular accident include transient ischemic attack within past 6 month ; Pulmonary hemorrhage/bleeding event &gt; Common Toxicity Criteria Adverse Effects ( CTCAE ) Grade 2 within 4 week first dose study drug ; 11 . ( 7. continue ) Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week first dose study drug ; Serious nonhealing wound , ulcer , bone fracture ; Evidence history bleed diathesis coagulopathy 12 . Uncontrolled hypertension define systolic blood pressure &gt; 140 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management . 13 . Major surgery , open biopsy significant traumatic injury within 4 week first study drug . 14 . Use St. John 's Wort rifampin ( rifampicin ) . 15 . Pregnancy woman childbearing potential men sexually active willing/able use medically acceptable form contraception ; exclusion necessary treatment involve study may significantly teratogenic . 16 . No tissue provide histopathologic review QRTPCR analysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Radiation</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>XRT</keyword>
</DOC>